Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis.

Gebremariam T, Alkhazraji S, Soliman SSM, Gu Y, Jeon HH, Zhang L, French SW, Stevens DA, Edwards JE Jr, Filler SG, Uppuluri P, Ibrahim AS.

Sci Adv. 2019 Jun 12;5(6):eaaw1327. doi: 10.1126/sciadv.aaw1327. eCollection 2019 Jun.

2.

CotH3 mediates fungal invasion of host cells during mucormycosis.

Gebremariam T, Liu M, Luo G, Bruno V, Phan QT, Waring AJ, Edwards JE Jr, Filler SG, Yeaman MR, Ibrahim AS.

J Clin Invest. 2014 Jan;124(1):237-50. doi: 10.1172/JCI71349. Epub 2013 Dec 20.

3.

Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis.

Gebremariam T, Lin L, Liu M, Kontoyiannis DP, French S, Edwards JE Jr, Filler SG, Ibrahim AS.

J Clin Invest. 2016 Jun 1;126(6):2280-94. doi: 10.1172/JCI82744. Epub 2016 May 9.

4.

The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice.

Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, Edwards JE Jr, Filler SG, Ibrahim AS.

J Clin Invest. 2010 Jun;120(6):1914-24. doi: 10.1172/JCI42164. Epub 2010 May 17.

5.

Inhibition of EGFR Signaling Protects from Mucormycosis.

Watkins TN, Gebremariam T, Swidergall M, Shetty AC, Graf KT, Alqarihi A, Alkhazraji S, Alsaadi AI, Edwards VL, Filler SG, Ibrahim AS, Bruno VM.

MBio. 2018 Aug 14;9(4). pii: e01384-18. doi: 10.1128/mBio.01384-18.

6.

The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis.

Ibrahim AS, Gebremariam T, Lin L, Luo G, Husseiny MI, Skory CD, Fu Y, French SW, Edwards JE Jr, Spellberg B.

Mol Microbiol. 2010 Aug;77(3):587-604. doi: 10.1111/j.1365-2958.2010.07234.x. Epub 2010 Jun 1.

7.

PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis.

Baldin C, Soliman SSM, Jeon HH, Alkhazraji S, Gebremariam T, Gu Y, Bruno VM, Cornely OA, Leather HL, Sugrue MW, Wingard JR, Stevens DA, Edwards JE Jr, Ibrahim AS.

J Clin Microbiol. 2018 Sep 25;56(10). pii: e00746-18. doi: 10.1128/JCM.00746-18. Print 2018 Oct.

8.

Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.

Gebremariam T, Wiederhold NP, Alqarihi A, Uppuluri P, Azie N, Edwards JE Jr, Ibrahim AS.

J Antimicrob Chemother. 2017 Feb;72(2):462-466. doi: 10.1093/jac/dkw433. Epub 2016 Oct 24.

9.

Heat-killed yeast protects diabetic ketoacidotic-steroid treated mice from pulmonary mucormycosis.

Luo G, Gebremariam T, Clemons KV, Stevens DA, Ibrahim AS.

Vaccine. 2014 Jun 17;32(29):3573-6. doi: 10.1016/j.vaccine.2014.04.086. Epub 2014 May 6.

10.

Pulmonary defense mechanisms against opportunistic fungal pathogens.

Waldorf AR.

Immunol Ser. 1989;47:243-71. Review.

PMID:
2490078
11.

Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of Rhizopus oryzae.

Bellanger AP, Tatara AM, Shirazi F, Gebremariam T, Albert ND, Lewis RE, Ibrahim AS, Kontoyiannis DP.

J Infect Dis. 2016 Jul 1;214(1):114-21. doi: 10.1093/infdis/jiw090. Epub 2016 Mar 16.

12.

Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection.

Ben-Ami R, Lewis RE, Tarrand J, Leventakos K, Kontoyiannis DP.

Antimicrob Agents Chemother. 2010 Jan;54(1):484-90. doi: 10.1128/AAC.00956-09. Epub 2009 Oct 26.

13.

Pathways of Pathogenicity: Transcriptional Stages of Germination in the Fatal Fungal Pathogen Rhizopus delemar.

Sephton-Clark PCS, Muñoz JF, Ballou ER, Cuomo CA, Voelz K.

mSphere. 2018 Sep 26;3(5). pii: e00403-18. doi: 10.1128/mSphere.00403-18.

14.

Host-iron assimilation: pathogenesis and novel therapies of mucormycosis.

Ibrahim AS.

Mycoses. 2014 Dec;57 Suppl 3:13-7. doi: 10.1111/myc.12232. Epub 2014 Sep 1. Review.

15.

Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Luo G, Gebremariam T, Lee H, French SW, Wiederhold NP, Patterson TF, Filler SG, Ibrahim AS.

Antimicrob Agents Chemother. 2013 Jul;57(7):3340-7. doi: 10.1128/AAC.00313-13. Epub 2013 May 6.

16.

Ketoacidosis alone does not predispose to mucormycosis by Lichtheimia in a murine pulmonary infection model.

Schulze B, Rambach G, Schwartze VU, Voigt K, Schubert K, Speth C, Jacobsen ID.

Virulence. 2017 Nov 17;8(8):1657-1667. doi: 10.1080/21505594.2017.1360460. Epub 2017 Aug 24.

17.

The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr, Spellberg BJ.

J Clin Invest. 2007 Sep;117(9):2649-57.

18.

Pathogenesis of mucormycosis.

Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP.

Clin Infect Dis. 2012 Feb;54 Suppl 1:S16-22. doi: 10.1093/cid/cir865. Review.

19.

An integrated genomic and transcriptomic survey of mucormycosis-causing fungi.

Chibucos MC, Soliman S, Gebremariam T, Lee H, Daugherty S, Orvis J, Shetty AC, Crabtree J, Hazen TH, Etienne KA, Kumari P, O'Connor TD, Rasko DA, Filler SG, Fraser CM, Lockhart SR, Skory CD, Ibrahim AS, Bruno VM.

Nat Commun. 2016 Jul 22;7:12218. doi: 10.1038/ncomms12218.

20.

VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Gebremariam T, Wiederhold NP, Fothergill AW, Garvey EP, Hoekstra WJ, Schotzinger RJ, Patterson TF, Filler SG, Ibrahim AS.

Antimicrob Agents Chemother. 2015 Dec;59(12):7815-7. doi: 10.1128/AAC.01437-15. Epub 2015 Sep 14.

Supplemental Content

Support Center